Abstract:BackgroundHirame novirhabdovirus (HIRRV) can infect a wide range of marine and freshwater fish, causing huge economic losses to aquaculture industry. Vaccine development, especially oral vaccine, has become an effective and convenient way to control aquatic infectious diseases. HIRRV glycoprotein (G), an immunogenic viral protein is a potential vaccine candidate for prevention of the disease. Here, we aimed to construct a recombinant Lactococcus lactis strain expressing HIRRV-G on the cell surface as an oral vaccine to prevent HIRRV.ResultsGlycoprotein gene of HIRRV was successfully cloned and expressed in L. lactis NZ9000 in a surface-displayed form, yielding Ll:pSLC-G. An approximately 81 kDa recombinant G protein (containing LysM anchoring motif) was confirmed by SDS-PAGE, western blotting and mass spectrometry analysis. The surface-displayed G protein was also verified by immunofluorescence and flow cytometry assays. Furthermore, to evaluate the potential of Ll:pSLC-G as oral vaccine candidate, flounders were continuously fed with commercial diet pellets coated with 1.0 × 109 cfu/g of induced Ll:pSLC-G for 1 week. Four weeks later, booster vaccination was performed with the same procedure. Compared with the controls, Ll:pSLC-G elicited significantly higher levels of specific IgM against HIRRV in flounder gut mucus at the second week and in serum at the fourth week (p < 0.05). Meanwhile, oral immunization with Ll:pSLC-G could provide 60.7% protection against HIRRV infection and a significantly lower virus load was detected than the controls on the third day post-challenge (p < 0.01). Moreover, on the first day post 1-week feeding, approximately 104–105 recombinant L. lactis cells were detected in every gram of foregut, midgut and hindgut of flounder, which were mainly localized at the bottom of gut mucus layer; and on day 21, 102–103 L. lactis cells could still be recovered.ConclusionsHIRRV-G protein was successfully expressed on the surface of L. lactis cells, which could trigger mucosal and humoral immune response of flounder and provide considerable immune protection against HIRRV. It suggests that genetically engineered L. lactis expressing G protein can be employed as a promising oral vaccine against HIRRV infection.

Development of monoclonal antibody against glycoprotein of hirame novirhabdovirus (HIRRV) with virus neutralizing activity

Development of Monoclonal Antibodies Against Southern Rice Black-Streaked Dwarf Virus and Rice Black-Streaked Dwarf Virus and Their Application in Virus Detection

Development and characterization of two monoclonal antibodies against grouper iridovirus 55L and 97L proteins

Expression and Immunogenic Comparison of VP2 and VP3 from Marine Birnavirus

Surface display of hirame novirhabdovirus (HIRRV) G protein in Lactococcus lactis and its immune protection in flounder (Paralichthys olivaceus)

Generation of Neutralizing and Non-Neutralizing Monoclonal Antibodies Against H7N9 Influenza Virus.

Preparation and Identification of Monoclonal Antibody Against Cytolysin of Vibrio Vulnificus

Development and application of a monoclonal antibody against grouper iridovirus (GIV) major capsid protein

Development of Two Potential Diagnostic Monoclonal Antibodies Against Human Cytomegalovirus Glycoprotein B

The development of RT-RPA and CRISPR-Cas12a based assay for sensitive detection of Hirame novirhabdovirus

A Novel Polyclonal Antibody Against Human Cytomegalovirus: General Characteristics and Potential Application in Diagnosis

Study on the Recombinant Expression of Hantaan Virus Protein N and the Establishment and Application of Rnp-Igm Direct Capture ELISA

Evaluation of Panel of Neutralising Murine Monoclonal Antibodies and a Humanised Bispecific Antibody Against Influenza A(H1N1)pdm09 Virus Infection in a Mouse Model.

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Development of broadly neutralizing antibodies targeting the cytomegalovirus subdominant antigen gH

Preparation of Antibody against Rabies Virus and Development of ELISA Method for Determination of Rabies Virus Antigen

Expression and characterization of recombinant antibodies against H7 subtype avian influenza virus and their diagnostic potential

Development of a monoclonal antibody against PRRSV glycoprotein 3 using an immuodominant peptide as immunogen

Preparation and identification of monoclonal antibody specific to the V region of rabies virus G protein

Broad neutralization of CSFV with novel monoclonal antibodies in vivo

Generation Of Monoclonal Antibodies Against Variable Epitopes Of The M Protein Of Rabies Virus